Sign in

NCT07797166Not yet recruiting

Assessment of Six-minute Walking Distance Between Sea Level LA vs. High Altitude HA After Re-ascent in Patients With Pulmonary Arterial Hypertension PAH

Effect of a One-week Descent From 2850m to Sea Level and Re-ascent in Patients With Pulmonary Arterial Hypertension and Healthy Controls Permanently Living > 2600m on Pulmonary Hemodynamics, Exercise Capacity, Blood Oxygenation, Sleep Disordered Breathing and Further Outcomes

Source: ClinicalTrials.gov · Last updated 1 Sept 2026

Brief summary (registry, in English)

To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on six-minute walking distance and other scores in patients with pulmonary arterial hypertension PAH, who live permanently \>2600m.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
20 (estimated)
First submitted
17 Aug 2026
Start date
25 Sept 2026
Primary completion date
4 Oct 2026
Lead sponsor
Silvia Ulrich Somaini
NCT number
NCT07797166

What you commit to

  • Study type: Interventional
  • Planned participants: 20
  • From 25 Sept 2026 to the primary completion date, 4 Oct 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, severe smokers (\>20 cigarettes/day)

Other illness

  • unstable condition

Lab values

  • Relevant concomitant other disease of the heart, kidney, liver, blood (anemia hemoglobin\<11 g/dl)

Age

  • Age \<18 years or \>80 years

Other

  • Patients who cannot follow the study investigations
  • Patient permanently living \< 2600m.
  • Patients who traveled and stayed overnight at altitudes \<2000 m in the past 4 weeks.
  • Severely hypoxemic patients at Quito permanently having persistent SpO2 (oxygen saturation by pulseoximetry) \<80% on ambient air.
  • Patient with a non-corrected ventricular septum defect

Who the study is looking for

  • Adult patients aged 18-80 years and of all genders
  • Permanent residence \> 2600 m
  • Diagnosis of pulmonary arterial hypertension PAH (PAHHA-Group) according to guidelines
  • Patients are stable on therapy
  • NYHA (new york heart association) functional class I-III.
  • written informed consent to participate in the study.

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University Hospital of Zurich
Coordinator of this site? Confirm its status
ZurichSwitzerlandUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.